[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Eyemart Express Ltd\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":95},{"warningLetters":4,"total":94},[5,31,51,72],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},21672,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2026-10-13T04:00:00Z\">10\u002F13\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-09-11T04:00:00Z\">09\u002F11\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frdm-express-inc-729223-09112026\">RDM Express Inc.\u003C\u002Fa>","Human Foods Program","CGMP\u002FFood\u002FPrepared, Packed or Held Under Insanitary Conditions\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Boris Dinerman\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>RDM Express Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2000 McKinnon Ave Bldg 427, Unit #12\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>San Francisco\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>94124\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6), (b)(7)(C)\"> (b)(6), (b)(7)(C)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Human Foods Program\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>September 11, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Re: CMS #729223\u003C\u002Fp>\u003Cp>Dear Mr. Dinerman:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your manufacturing facility, located at 2000 McKinnon Ave, Bldg 427, Unit #12, San Francisco, CA 94124, between February 18, 2026, and March 10, 2026. During our inspection of your facility, an FDA investigator found serious violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP &amp; PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117). Based on FDA's inspectional findings and analytical results for finished product samples of your Fermented Cabbage, we have determined that your ready-to-eat (RTE) Fermented Cabbage\u002FSour Cabbage products are adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 342(a)(4)], in that they were prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth, or whereby they may have been rendered injurious to health. In addition, failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provisions of the CGMP &amp; PC rule (located in Subparts A, C, D, E, F, and G of Part 117) is prohibited by section 301(uu) of the Act [21 U.S.C. § 331(uu)]. You may find the Act and FDA's regulations through links on FDA's website at www.fda.gov.\u003C\u002Fp>\u003Cp>Further, a review of the Russian Style Kvas Drink, Sour Cabbage, and Half Sour Pickles product labels collected during the inspection revealed significant violations of the labeling regulations for foods under 21 CFR Part 101. These violations render your product to be misbranded within the meaning of section 403 of the Act [21 U.S.C. § 343], as discussed below.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection, the FDA investigator issued your facility a Form FDA 483 (FDA-483), Inspectional Observations. To date, FDA has not received your written response. After reviewing the inspectional findings, we are issuing this letter to advise you of FDA’s concerns.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Hazard Analysis and Risk-Based Preventive Controls (21 CFR Part 117, Subpart C)\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>1. You did not identify and evaluate known or reasonably foreseeable hazards to determine whether they required preventive controls, as required by 21 CFR 117.130(a)(1).\u003C\u002Fp>\u003Cp>Specifically, you manufacture a refrigerated, RTE Fermented Cabbage\u002FSour Cabbage product. However, the hazard analysis in your document titled “Food Safety Plan for Acidified &amp; Fermented Foods” dated April 30, 2025, did not identify and evaluate the following hazards requiring a preventive control:\u003C\u002Fp>\u003Cp>a. Recontamination with environmental pathogens (e.g., Listeria monocytogenes)\u003C\u002Fp>\u003Cp>Employees \u003Cstrong>(b)(4)\u003C\u002Fstrong> package Fermented Cabbage\u002FSour Cabbage into \u003Cstrong>(b)(4)\u003C\u002Fstrong> pails and \u003Cstrong>(b)(4)\u003C\u002Fstrong> containers in the production room, under ambient conditions, exposing RTE product to the environment. The packaged food does not receive any further lethal treatment or otherwise include a control measure (such as a formulation lethal to the pathogen) that would significantly minimize pathogens. A knowledgeable person manufacturing\u002Fprocessing food in your circumstances would identify contamination with environmental pathogens as a hazard requiring a preventive control (e.g., sanitation controls). Sanitation controls include procedures, practices, and processes to ensure that the facility is maintained in a sanitary condition adequate to significantly minimize or prevent hazards such as environmental pathogens and biological hazards due to employee handling (see 21 CFR 117.135(c)(3)).\u003C\u002Fp>\u003Cp>You have a document titled “PROCEDURE FOR CLEANING AND SANITIZING OF EQUIPMENT” which, among other things, lists steps such as \u003Cstrong>(b)(4)\u003C\u002Fstrong>, washing, rinsing, \u003Cstrong>(b)(4)\u003C\u002Fstrong> drying. However, this document does not include procedures for monitoring, corrective actions, and verification.\u003C\u002Fp>\u003Cp>Furthermore, you provided copies of your “Sanitation Checklist”, “Sanitation Log”, and “Deep Cleaning Checklist”. However, none of these documents identify what equipment was cleaned and sanitized or who performed the cleaning.\u003C\u002Fp>\u003Cp>Furthermore, you provided a copy of your “Hygiene Checklist” which indicates that you monitor for glove use and handwashing \u003Cstrong>(b)(4)\u003C\u002Fstrong>. This frequency is insufficient to ensure that the hazard of pathogen contamination is controlled during production of fermented cabbage. Additionally, this “Hygiene Checklist” includes a “Compliant” column, which was marked “N” (no) by an employee with initials “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” for \u003Cstrong>(b)(4)\u003C\u002Fstrong> dates recorded between October 27, 2025 and February 23, 2026. However, there is no documentation identifying the cause of non-compliance or any corrective actions taken in response.\u003C\u002Fp>\u003Cp>None of the above-mentioned records were reviewed for completeness and accuracy within seven working days of the records being created, as required under 21 CFR 117.165(a)(4).\u003C\u002Fp>\u003Cp>Lastly, you do not have an environmental monitoring program, nor do you conduct any environmental monitoring to verify that your sanitation procedures are effectively controlling the hazard of environmental pathogens, such as Listeria monocytogenes.\u003C\u002Fp>\u003Cp>b. Parasites (e.g., \u003Cem>Cyclospora\u003C\u002Fem>) and viruses (e.g., Norovirus and Hepatitis A) in \u003Cstrong>(b)(4)\u003C\u002Fstrong> cranberries\u003C\u002Fp>\u003Cp>You receive \u003Cstrong>(b)(4)\u003C\u002Fstrong> cranberries, which is an ingredient used in your refrigerated, RTE Fermented Cabbage\u002FSour Cabbage product. Cranberries, like other berries, have been associated with parasites such as \u003Cem>Cyclospora\u003C\u002Fem> and viruses such as Norovirus and Hepatitis A. Oocysts of \u003Cem>Cyclospora\u003C\u002Fem> can be shed by infected hosts during harvesting, and depending on time and temperature, \u003Cstrong>(b)(4)\u003C\u002Fstrong> may not be effective in appropriately destroying \u003Cem>Cyclospora\u003C\u002Fem>. Similarly, Norovirus and Hepatitis A are known to persist on berry surfaces and are not reliably inactivated by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your fermentation process does not appear adequate to control the hazard of growth and\u002For survival of parasites, such as \u003Cem>Cyclospora\u003C\u002Fem>, and viruses, such as Norovirus and Hepatitis A, if they are already present in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> cranberries at receiving. Additionally, your product’s formulation does not provide an adequate “kill step” for Norovirus, Hepatitis A, or \u003Cem>Cyclospora\u003C\u002Fem>. Finally, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> cranberries are used in a RTE application and do not undergo a validated lethality step. A knowledgeable person manufacturing\u002Fprocessing food in your circumstances would identify the above-mentioned parasites and viruses as a hazard requiring a preventive control (e.g., a supply-chain control) in this ingredient. Further, a facility that identifies raw materials and other ingredients that require a supply-chain-applied control due to a hazard must establish and implement a risk-based supply-chain program for those raw materials and ingredients (see 21 CFR 117.405(a)(1)). The supply-chain program must include using approved suppliers and conducting supplier verification activities (see 21 CFR 117.410).\u003C\u002Fp>\u003Cp>2. Your written process preventive control, monitoring, and verification procedures were not appropriate to significantly minimize or prevent hazards requiring preventive controls, as required by 21 CFR 117.135(c)(1).\u003C\u002Fp>\u003Cp>Specifically, your document titled “Food Safety Plan for Acidified &amp; Fermented Foods” dated April 30, 2025, identifies a “preventive measure” of “Finished product pH below \u003Cstrong>(b)(4)\u003C\u002Fstrong>” to control the hazard of “Pathogens: Clostridium botulinum, Listeria monocytogenes” at your “pH Testing (\u003Cstrong>(b)(4)\u003C\u002Fstrong>)” step. However, we note that pH alone is insufficient to control all relevant pathogens of concern. While reducing pH before packaging may limit pathogen growth, your process preventive control must also account for pathogen survival. \u003Cem>Listeria monocytogenes\u003C\u002Fem> is an acid-tolerant pathogen that can survive the fermentation process if introduced through raw ingredients or environmental contamination, and may persist even at a pH of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Similarly, product formulation alone does not prevent or eliminate vegetative bacterial pathogens—such as \u003Cem>Listeria\u003C\u002Fem>, \u003Cem>E. coli\u003C\u002Fem>, and \u003Cem>Salmonella\u003C\u002Fem>—that may be associated with incoming raw ingredients.\u003C\u002Fp>\u003Cp>On February 25, 2026, FDA collected a sample of RTE fermented cabbage from your facility (sample # 1319005) and found and pH range of 4.0-4.17, a range at which \u003Cem>Listeria monocytogenes\u003C\u002Fem> is known to survive, and a water activity of 0.98. This water activity level represents an optimal moisture environment for bacteria to survive or thrive, further demonstrating that pH alone does not constitute an adequate preventive control when other intrinsic factors remain permissive for pathogen survival and growth.\u003C\u002Fp>\u003Cp>Furthermore, your written process preventive control document titled “Critical Control Point (CCP) Chart” references an SOP titled \"PROCEDURE FOR PH METER TESTING AND CALIBRATION\" for pH monitoring. Even setting aside the scientific inadequacy of pH as a standalone control, several deficiencies were identified in how you monitor and verify pH in practice:\u003C\u002Fp>\u003Cul>\u003Cli>The SOP does not clearly indicate when pH verification occurs in relation to fermentation completion, cold storage (\u003Cstrong>(b)(4)\u003C\u002Fstrong> days), or packaging operations. Additionally, your “pH Measurement Log (Daily)” records do not indicate what time pH measurements were taken, such that it is not possible to determine whether monitoring is occurring at meaningful or consistent points in the process.\u003C\u002Fli>\u003Cli>Contrary to the SOP, your actual pH testing practice is to collect a sample from the \u003Cstrong>(b)(4)\u003C\u002Fstrong> barrel after fermentation is completed \u003Cstrong>(b)(4)\u003C\u002Fstrong> moving the barrel to the cooler. \u003Cstrong>(b)(4)\u003C\u002Fstrong> of a large barrel does not constitute a representative sample of the batch and does not adequately characterize the pH of the product as a whole. The RTE fermented cabbage is packaged into finished product containers approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> days \u003Cstrong>(b)(4)\u003C\u002Fstrong> processing, and you stated you do not test pH at the time of packaging. Given the time elapsed between initial pH measurement and packaging, the absence of pH testing at packaging represents a gap in your ability to verify that the product meets the established critical limit prior to distribution.\u003C\u002Fli>\u003Cli>The SOP indicates the pH meter should be calibrated \u003Cstrong>(b)(4)\u003C\u002Fstrong>, or whenever readings are in doubt. However, your pH calibration records show the meter is only calibrated \u003Cem>once per week\u003C\u002Fem>, at the beginning of each week.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>You have not provided a validation study or supporting scientific literature demonstrating that your fermentation process—including all applicable \u003Cstrong>(b)(4)\u003C\u002Fstrong>—adequately controls the pathogens of concern. Validation approaches such as a challenge study may be used to demonstrate that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> achieves adequate process preventive control. Additionally, if you can consistently demonstrate that the finished packaged product achieves and maintains a pH of ≤ 4.2, this would provide an additional safety margin by keeping the product well below the minimum inhibitory pH threshold for \u003Cem>Clostridium botulinum\u003C\u002Fem>. As adequate controls are developed, you must also ensure that appropriate preventive control management components—including monitoring, corrective actions, and verification procedures—are established and implemented in accordance with 21 CFR Part 117, Subpart C.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Misbranding\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>1. Your Russian Style Kvas Drink product is misbranded within the meaning of section 403(i)(2) of the Act [21 U.S.C. § 343(i)(2)] in that the product is fabricated from two or more ingredients and the label fails to declare the common or usual name of each ingredient, as required by 21 CFR 101.4(a)(1). Specifically, your Russian Style Kvas Drink product label declares the ingredient “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”, which is not the common or usual name of the ingredient.\u003C\u002Fp>\u003Cp>2. Your Russian Style Kvas Drink product is misbranded within the meaning of Section 403(f) of the Act [21 U.S. C. 343(f)] because the label bears a foreign language (Russian)but does not repeat all required labeling information in the foreign language (Russian). The mandatory label information is present in English, but the label does not repeat all required information in Russian, as required by 21 CFR 101.15(c)(2).\u003C\u002Fp>\u003Cp>3. Your Russian Style Kvas Drink product is misbranded within the meaning of Section 403(q) of the Act [21 U.S. C. 343(q)] because the Nutrition Facts label is not in accordance with the requirements under 21 CFR 101.9. For example, the Nutrition Facts label lacks declaration for added sugars, and the required vitamins and minerals, vitamin D and potassium, as required by 21 CFR 101.9(c).\u003C\u002Fp>\u003Cp>4. Your Sour Cabbage and Half Sour Pickles products are misbranded within the meaning of section 403(e)(2) [21 U.S.C. §343(e)(2)] of the Act. Specifically:\u003C\u002Fp>\u003Cp>a. Your Sour Cabbage product label declares the net quantity of contents in terms of weight; however, it must be declared in terms of fluid measure, as required in 21 CFR 101.7(a).\u003C\u002Fp>\u003Cp>b. Your Half Sour Pickles product label declares the net quantity of contents as ‘32 FL OZ’ but fails to include the largest whole unit of liquid measure in parentheses. Because 32 fluid ounces equals one quart, the declaration must be expressed as ‘32 fl oz (1 qt),’ as required by 21 CFR 101.7(j)(1) and shown in 21 CFR 101.7(m)(3).\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including applicable FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\u003Cp>\u003Cstrong>In addition to the violations described above, we offer the following comments:\u003C\u002Fstrong>\u003C\u002Fp>\u003Cul>\u003Cli>Your Half Sour Pickles and Russian Style Kvas Drink product labels do not include the street address of the place of business of the manufacturer, packer, or distributor, as required by 21 CFR 101.5(d). We note, however, that the street address may be omitted if it is shown in a current city directory or telephone directory.\u003C\u002Fli>\u003Cli>Your Sour Cabbage product label identifies the firm's name and place of business; however, it does not include an appropriate qualifying phrase (e.g., \"Distributed by\") in conjunction with the place of business as required under 21 CFR 101.5(c). Although the statement \"Distributed by RDM Express Inc.\" appears toward the bottom of the label, it does not appear to be part of the place of business declaration, and it is unclear whether this statement is intended to satisfy the requirements of 21 CFR 101.5(c).\u003C\u002Fli>\u003Cli>The net quantity of contents for your Half Sour Pickles product uses the term “Net Wt.” in conjunction with a declaration expressed in fluid measure (i.e., fl. oz). We note that 21 CFR 101.7(j)(3) provides that the use of the terms “net” or “net contents” in terms of fluid measure is optional.\u003C\u002Fli>\u003Cli>The common or usual name \"Russian Style Kvas Drink\" may not satisfy the requirements of 21 CFR 101.3(b)(2). A more descriptive term, in accordance with 21 CFR 101.3(b)(3), may be more appropriate to accurately convey the nature of this product as a Russian style malt-based drink and ensure and ensure consumers have a clear understanding of what they are purchasing.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Your written response should be sent electronically to: HFP-OCE-ConventionalFoods@fda.hhs.gov, copying Clarice J. Ahn, Compliance Officer, at Clarice.Ahn@fda.hhs.gov. If you have any questions regarding this letter, you may contact Clarice J. Ahn, Compliance Officer, at Clarice.Ahn@fda.hhs.gov. Please reference CMS #729223 on any submissions and within the subject line of any emails to us.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Maria S. Knirk, JD MBA\u003Cbr>Director, Office of Enforcement\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Human Foods Program\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Boris Dinerman\n\nRecipient Title\n\nCEO\n\nRDM Express Inc.\n\n2000 McKinnon Ave Bldg 427, Unit #12\n\nSan Francisco, CA 94124\n\nUnited States\n\n(b)(6), (b)(7)(C)\n\nIssuing Office:\n\nHuman Foods Program\n\nUnited States\n\nSeptember 11, 2026\nWARNING LETTER\nRe: CMS #729223\nDear Mr. Dinerman:\nThe United States Food and Drug Administration (FDA) inspected your manufacturing facility, located at 2000 McKinnon Ave, Bldg 427, Unit #12, San Francisco, CA 94124, between February 18, 2026, and March 10, 2026. During our inspection of your facility, an FDA investigator found serious violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP & PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117). Based on FDA's inspectional findings and analytical results for finished product samples of your Fermented Cabbage, we have determined that your ready-to-eat (RTE) Fermented Cabbage\u002FSour Cabbage products are adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 342(a)(4)], in that they were prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth, or whereby they may have been rendered injurious to health. In addition, failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provisions of the CGMP & PC rule (located in Subparts A, C, D, E, F, and G of Part 117) is prohibited by section 301(uu) of the Act [21 U.S.C. § 331(uu)]. You may find the Act and FDA's regulations through links on FDA's website at www.fda.gov.\nFurther, a review of the Russian Style Kvas Drink, Sour Cabbage, and Half Sour Pickles product labels collected during the inspection revealed significant violations of the labeling regulations for foods under 21 CFR Part 101. These violations render your product to be misbranded within the meaning of section 403 of the Act [21 U.S.C. § 343], as discussed below.\nAt the conclusion of the inspection, the FDA investigator issued your facility a Form FDA 483 (FDA-483), Inspectional Observations. To date, FDA has not received your written response. After reviewing the inspectional findings, we are issuing this letter to advise you of FDA’s concerns.\nHazard Analysis and Risk-Based Preventive Controls (21 CFR Part 117, Subpart C)\n1. You did not identify and evaluate known or reasonably foreseeable hazards to determine whether they required preventive controls, as required by 21 CFR 117.130(a)(1).\nSpecifically, you manufacture a refrigerated, RTE Fermented Cabbage\u002FSour Cabbage product. However, the hazard analysis in your document titled “Food Safety Plan for Acidified & Fermented Foods” dated April 30, 2025, did not identify and evaluate the following hazards requiring a preventive control:\na. Recontamination with environmental pathogens (e.g., Listeria monocytogenes)\nEmployees (b)(4) package Fermented Cabbage\u002FSour Cabbage into (b)(4) pails and (b)(4) containers in the production room, under ambient conditions, exposing RTE product to the environment. The packaged food does not receive any further lethal treatment or otherwise include a control measure (such as a formulation lethal to the pathogen) that would significantly minimize pathogens. A knowledgeable person manufacturing\u002Fprocessing food in your circumstances would identify contamination with environmental pathogens as a hazard requiring a preventive control (e.g., sanitation controls). Sanitation controls include procedures, practices, and processes to ensure that the facility is maintained in a sanitary condition adequate to significantly minimize or prevent hazards such as environmental pathogens and biological hazards due to employee handling (see 21 CFR 117.135(c)(3)).\nYou have a document titled “PROCEDURE FOR CLEANING AND SANITIZING OF EQUIPMENT” which, among other things, lists steps such as (b)(4), washing, rinsing, (b)(4) drying. However, this document does not include procedures for monitoring, corrective actions, and verification.\nFurthermore, you provided copies of your “Sanitation Checklist”, “Sanitation Log”, and “Deep Cleaning Checklist”. However, none of these documents identify what equipment was cleaned and sanitized or who performed the cleaning.\nFurthermore, you provided a copy of your “Hygiene Checklist” which indicates that you monitor for glove use and handwashing (b)(4). This frequency is insufficient to ensure that the hazard of pathogen contamination is controlled during production of fermented cabbage. Additionally, this “Hygiene Checklist” includes a “Compliant” column, which was marked “N” (no) by an employee with initials “(b)(4)” for (b)(4) dates recorded between October 27, 2025 and February 23, 2026. However, there is no documentation identifying the cause of non-compliance or any corrective actions taken in response.\nNone of the above-mentioned records were reviewed for completeness and accuracy within seven working days of the records being created, as required under 21 CFR 117.165(a)(4).\nLastly, you do not have an environmental monitoring program, nor do you conduct any environmental monitoring to verify that your sanitation procedures are effectively controlling the hazard of environmental pathogens, such as Listeria monocytogenes.\nb. Parasites (e.g., Cyclospora) and viruses (e.g., Norovirus and Hepatitis A) in (b)(4) cranberries\nYou receive (b)(4) cranberries, which is an ingredient used in your refrigerated, RTE Fermented Cabbage\u002FSour Cabbage product. Cranberries, like other berries, have been associated with parasites such as Cyclospora and viruses such as Norovirus and Hepatitis A. Oocysts of Cyclospora can be shed by infected hosts during harvesting, and depending on time and temperature, (b)(4) may not be effective in appropriately destroying Cyclospora. Similarly, Norovirus and Hepatitis A are known to persist on berry surfaces and are not reliably inactivated by (b)(4). Your fermentation process does not appear adequate to control the hazard of growth and\u002For survival of parasites, such as Cyclospora, and viruses, such as Norovirus and Hepatitis A, if they are already present in the (b)(4) cranberries at receiving. Additionally, your product’s formulation does not provide an adequate “kill step” for Norovirus, Hepatitis A, or Cyclospora. Finally, the (b)(4) cranberries are used in a RTE application and do not undergo a validated lethality step. A knowledgeable person manufacturing\u002Fprocessing food in your circumstances would identify the above-mentioned parasites and viruses as a hazard requiring a preventive control (e.g., a supply-chain control) in this ingredient. Further, a facility that identifies raw materials and other ingredients that require a supply-chain-applied control due to a hazard must establish and implement a risk-based supply-chain program for those raw materials and ingredients (see 21 CFR 117.405(a)(1)). The supply-chain program must include using approved suppliers and conducting supplier verification activities (see 21 CFR 117.410).\n2. Your written process preventive control, monitoring, and verification procedures were not appropriate to significantly minimize or prevent hazards requiring preventive controls, as required by 21 CFR 117.135(c)(1).\nSpecifically, your document titled “Food Safety Plan for Acidified & Fermented Foods” dated April 30, 2025, identifies a “preventive measure” of “Finished product pH below (b)(4)” to control the hazard of “Pathogens: Clostridium botulinum, Listeria monocytogenes” at your “pH Testing ((b)(4))” step. However, we note that pH alone is insufficient to control all relevant pathogens of concern. While reducing pH before packaging may limit pathogen growth, your process preventive control must also account for pathogen survival. Listeria monocytogenes is an acid-tolerant pathogen that can survive the fermentation process if introduced through raw ingredients or environmental contamination, and may persist even at a pH of (b)(4). Similarly, product formulation alone does not prevent or eliminate vegetative bacterial pathogens—such as Listeria, E. coli, and Salmonella—that may be associated with incoming raw ingredients.\nOn February 25, 2026, FDA collected a sample of RTE fermented cabbage from your facility (sample # 1319005) and found and pH range of 4.0-4.17, a range at which Listeria monocytogenes is known to survive, and a water activity of 0.98. This water activity level represents an optimal moisture environment for bacteria to survive or thrive, further demonstrating that pH alone does not constitute an adequate preventive control when other intrinsic factors remain permissive for pathogen survival and growth.\nFurthermore, your written process preventive control document titled “Critical Control Point (CCP) Chart” references an SOP titled \"PROCEDURE FOR PH METER TESTING AND CALIBRATION\" for pH monitoring. Even setting aside the scientific inadequacy of pH as a standalone control, several deficiencies were identified in how you monitor and verify pH in practice:\nThe SOP does not clearly indicate when pH verification occurs in relation to fermentation completion, cold storage ((b)(4) days), or packaging operations. Additionally, your “pH Measurement Log (Daily)” records do not indicate what time pH measurements were taken, such that it is not possible to determine whether monitoring is occurring at meaningful or consistent points in the process.\nContrary to the SOP, your actual pH testing practice is to collect a sample from the (b)(4) barrel after fermentation is completed (b)(4) moving the barrel to the cooler. (b)(4) of a large barrel does not constitute a representative sample of the batch and does not adequately characterize the pH of the product as a whole. The RTE fermented cabbage is packaged into finished product containers approximately (b)(4) days (b)(4) processing, and you stated you do not test pH at the time of packaging. Given the time elapsed between initial pH measurement and packaging, the absence of pH testing at packaging represents a gap in your ability to verify that the product meets the established critical limit prior to distribution.\nThe SOP indicates the pH meter should be calibrated (b)(4), or whenever readings are in doubt. However, your pH calibration records show the meter is only calibrated once per week, at the beginning of each week.\nYou have not provided a validation study or supporting scientific literature demonstrating that your fermentation process—including all applicable (b)(4)—adequately controls the pathogens of concern. Validation approaches such as a challenge study may be used to demonstrate that the (b)(4) achieves adequate process preventive control. Additionally, if you can consistently demonstrate that the finished packaged product achieves and maintains a pH of ≤ 4.2, this would provide an additional safety margin by keeping the product well below the minimum inhibitory pH threshold for Clostridium botulinum. As adequate controls are developed, you must also ensure that appropriate preventive control management components—including monitoring, corrective actions, and verification procedures—are established and implemented in accordance with 21 CFR Part 117, Subpart C.\nMisbranding\n1. Your Russian Style Kvas Drink product is misbranded within the meaning of section 403(i)(2) of the Act [21 U.S.C. § 343(i)(2)] in that the product is fabricated from two or more ingredients and the label fails to declare the common or usual name of each ingredient, as required by 21 CFR 101.4(a)(1). Specifically, your Russian Style Kvas Drink product label declares the ingredient “(b)(4)”, which is not the common or usual name of the ingredient.\n2. Your Russian Style Kvas Drink product is misbranded within the meaning of Section 403(f) of the Act [21 U.S. C. 343(f)] because the label bears a foreign language (Russian)but does not repeat all required labeling information in the foreign language (Russian). The mandatory label information is present in English, but the label does not repeat all required information in Russian, as required by 21 CFR 101.15(c)(2).\n3. Your Russian Style Kvas Drink product is misbranded within the meaning of Section 403(q) of the Act [21 U.S. C. 343(q)] because the Nutrition Facts label is not in accordance with the requirements under 21 CFR 101.9. For example, the Nutrition Facts label lacks declaration for added sugars, and the required vitamins and minerals, vitamin D and potassium, as required by 21 CFR 101.9(c).\n4. Your Sour Cabbage and Half Sour Pickles products are misbranded within the meaning of section 403(e)(2) [21 U.S.C. §343(e)(2)] of the Act. Specifically:\na. Your Sour Cabbage product label declares the net quantity of contents in terms of weight; however, it must be declared in terms of fluid measure, as required in 21 CFR 101.7(a).\nb. Your Half Sour Pickles product label declares the net quantity of contents as ‘32 FL OZ’ but fails to include the largest whole unit of liquid measure in parentheses. Because 32 fluid ounces equals one quart, the declaration must be expressed as ‘32 fl oz (1 qt),’ as required by 21 CFR 101.7(j)(1) and shown in 21 CFR 101.7(m)(3).\nThis letter is not intended to be an all-inclusive statement of violations that may exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including applicable FDA regulations.\nThis letter notifies you of our concerns and provides you with an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and\u002For injunction.\nIn addition to the violations described above, we offer the following comments:\nYour Half Sour Pickles and Russian Style Kvas Drink product labels do not include the street address of the place of business of the manufacturer, packer, or distributor, as required by 21 CFR 101.5(d). We note, however, that the street address may be omitted if it is shown in a current city directory or telephone directory.\nYour Sour Cabbage product label identifies the firm's name and place of business; however, it does not include an appropriate qualifying phrase (e.g., \"Distributed by\") in conjunction with the place of business as required under 21 CFR 101.5(c). Although the statement \"Distributed by RDM Express Inc.\" appears toward the bottom of the label, it does not appear to be part of the place of business declaration, and it is unclear whether this statement is intended to satisfy the requirements of 21 CFR 101.5(c).\nThe net quantity of contents for your Half Sour Pickles product uses the term “Net Wt.” in conjunction with a declaration expressed in fluid measure (i.e., fl. oz). We note that 21 CFR 101.7(j)(3) provides that the use of the terms “net” or “net contents” in terms of fluid measure is optional.\nThe common or usual name \"Russian Style Kvas Drink\" may not satisfy the requirements of 21 CFR 101.3(b)(2). A more descriptive term, in accordance with 21 CFR 101.3(b)(3), may be more appropriate to accurately convey the nature of this product as a Russian style malt-based drink and ensure and ensure consumers have a clear understanding of what they are purchasing.\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\nYour written response should be sent electronically to: HFP-OCE-ConventionalFoods@fda.hhs.gov, copying Clarice J. Ahn, Compliance Officer, at Clarice.Ahn@fda.hhs.gov. If you have any questions regarding this letter, you may contact Clarice J. Ahn, Compliance Officer, at Clarice.Ahn@fda.hhs.gov. Please reference CMS #729223 on any submissions and within the subject line of any emails to us.\nSincerely,\n\u002FS\u002F\nMaria S. Knirk, JD MBA\nDirector, Office of Enforcement\nOffice of Compliance and Enforcement\nHuman Foods Program","RDM Express Inc.","rdm-express-inc-729223-09112026","2026-10-14T12:31:16.41489+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frdm-express-inc-729223-09112026","2026-11-17T01:02:03.701861+00:00","Warning Letter","Issued","2026-10-13","729223","Food & Beverages","Mr. Boris Dinerman","2026-10-14T12:32:21.242+00:00","VIA Electronic Mail","2026-09-11",{"id":32,"raw":33,"subject":38,"body_html":39,"body_text":40,"firm_name":16,"letter_id":41,"created_at":42,"fei_number":19,"letter_url":43,"updated_at":44,"action_type":22,"case_status":23,"posted_date":45,"marcs_cms_no":46,"product_type":26,"closeout_date":19,"issuing_office":47,"recipient_name":27,"body_fetched_at":48,"delivery_method":49,"recipient_title":19,"reference_number":19,"action_taken_date":50,"medical_device_id":19,"response_letter_date":19},2184,[34,35,36,37,38,13,13,13],"\u003Ctime datetime=\"2023-02-28T14:20:00Z\">02\u002F28\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-12-12T05:00:00Z\">12\u002F12\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frdm-express-inc-643578-12122022\">RDM Express Inc.\u003C\u002Fa>"," Division of Human and Animal Food Operations West V","Seafood HACCP\u002FCGMP for Foods\u002FAdulterated\u002FInsanitary Conditions","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>United Parcel Service\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Boris Dinerman\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>RDM Express Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2000 McKinnon Ave. Bldg. 427, Unit #12\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>San Francisco\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>94124\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Human and Animal Food Operations West V\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>December 12, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WL 643578&nbsp;\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Dinerman:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) inspected your ambient, refrigerated, and frozen warehouse facility, located at 2000 McKinnon Ave., Bldg. 427, Unit 12, San Francisco, CA 94124, from September 05-15, 2022. During the inspection, FDA investigators found serious violations of the seafood Hazard Analysis and Critical Control Point (HACCP) regulation, Title 21, Code of Federal Regulations (CFR), Part 123 (21 CFR Part 123), and the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP &amp; PC rule) (21 CFR Part 117). At the conclusion of the inspection, the FDA investigators issued a Form FDA 483, Inspectional Observations, listing the deviations found at your firm. In addition, FDA investigators collected filth samples from various areas within your warehouse facility. FDA laboratory analyses of the samples found the presence of rodent and insect activity throughout your facility.\u003C\u002Fp>\n\n\u003Cp>In accordance with 21 CFR § 123.6(g), failure of a processor of fish or fishery products to have and implement a HACCP plan that complies with this section or otherwise operate in accordance with the requirements of Part 123, renders the fish or fishery products adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 342(a)(4). Based on our inspectional findings and analytical results, we have determined that the food products stored at your facility, including the ready-to-eat, refrigerated, reduced oxygen packaging Herring Fillets in Oil, are adulterated within the meaning of section 402(a)(4) of the Act in that they have been prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth or rendered injurious to health. You may find the Act, the seafood HACCP regulation, the 4th edition of the Fish and Fisheries Products Hazards &amp; Controls Guidance, and further information about the CGMP &amp; PC rule through links in FDA's home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, FDA investigators issued you a Form FDA 483, Inspectional Observations. You have not submitted a response to address these violations. Based on our review of the inspectional findings, we are issuing this letter to advise you of FDA’s continuing concerns and to provide detailed information describing the findings at your facility.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Seafood HACCP\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>1. You must implement the monitoring procedures that you have listed in your HACCP plan, to comply with 21 CFR § 123.6 (b). However, your firm did not implement the following monitoring procedures as listed in your HACCP plan for Herring Fillets in Oil.\u003C\u002Fp>\n\n\u003Cp>a) You did not visually check the data generated by a temperature recording device during transit at your receiving critical control point (CCP) to control the listed hazards of C. botulinum toxin and histamine formation.\u003C\u002Fp>\n\n\u003Cp>Specifically, on August 29, 2022, you received the following Herring Fillets in Oil products:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Upon receipt of these reduced oxygen packaging (ROP), ready-to-eat (RTE) products, you did not review any transportation records as required by your HACCP plan. You explained to the investigator that your standard practice is \u003Cstrong>(b)(4)\u003C\u002Fstrong> to obtain a temperature upon receipt and record the temperature on your receiving log. This procedure is not what your plan requires, it is not adequate to ensure that proper temperatures were maintained during transit, and it is a repeat violation from your FDA inspection that ended on December 6, 2017.\u003C\u002Fp>\n\n\u003Cp>b) You did not check a continuous temperature recording for your cooler \u003Cstrong>(b)(4)\u003C\u002Fstrong> as required by your HACCP plan at your refrigerated storage CCP with a critical limit of “Cooler temperature of \u003Cstrong>(b)(4)\u003C\u002Fstrong>” to control for the listed hazards of pathogenic bacteria growth and toxin formation, C. botulinum toxin formation, and histamine formation. Specifically, your cooler does not have a continuous temperature monitoring device. Additionally, you stated to the investigator that your standard practice is to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. This procedure is not what your plan requires and is not adequate to ensure that a proper temperature is maintained in the cooler.\u003C\u002Fp>\n\n\u003Cp>Regarding the inadequacy of your monitoring, on September 7, 2022, our investigators used a calibrated traceable thermometer to take the following temperature readings from the cooler where you stored all your refrigerated seafood products, including ROP, RTE Herring Fillet in Oil:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>At 8:15 AM, the cooler temperature readout was 46.9°F\u003C\u002Fli>\n\t\u003Cli>At 1:30 PM, the cooler temperature readout was 54.6°F\u003C\u002Fli>\n\t\u003Cli>At 3:10 PM, the cooler temperature readout was 58.4°F\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Furthermore, you did not have documentation showing that the thermometers you use have been calibrated for accuracy to comply with 21 CFR § 123.8 (a)(2)(ii) for the calibration of process-monitoring instruments. These are repeat violations from your FDA inspection that ended on December 6, 2017. We note that during the inspection you moved all your seafood products from the cooler to the freezer. Further, you stated that all seafood products will be stored in the freezer until you are able to install a continuous monitoring system for the cooler.\u003C\u002Fp>\n\n\u003Cp>2. Because you chose to include a corrective action plan in your HACCP plan your described corrective actions must be appropriate to comply with 21 CFR § 123.7 (b). However, your corrective action plan for your Herring Fillets in Oil listed hazards of pathogenic bacteria growth and toxin formation, C. botulinum toxin formation, and histamine formation at the Receiving and Refrigerated Storage CCPs is not appropriate. Your corrective actions fail to ensure the cause of the deviation is corrected, such as discontinuing the use of the supplier until transit practices have improved and adjusting or repairing the cooler.\u003C\u002Fp>\n\n\u003Cp>Your response to this warning letter should include the disposition of the product affected by the temperature deviation during refrigerated storage, and a revised HACCP plan along with at least five production days of CCP monitoring records to demonstrate implementation.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Sanitation\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>1. You must monitor the conditions and practices during processing with sufficient frequency to ensure conformance with the current good manufacturing practice requirements in 21 CFR Part 117, Subpart B (CGMPs), that are both appropriate to your plant and the food being processed and relate to one of the areas specified in 21 CFR § 123.11(b)(1)-(8), to comply with 21 CFR § 123.11 (b). However, your firm did not monitor for the presence of pests in the food plant with sufficient frequency to ensure that pests are not allowed in any area, as required by 21 CFR § 117.35(C). This is related to the exclusion of pests from the food plant, 21 CFR § 123.11 (b)(8). Specifically, on September 7 and 8, 2022, our investigators observed the following in your ambient food storage area:\u003C\u002Fp>\n\n\u003Cp>a) There were many large, rat apparent rodent excreta pellets (AREPs) found along the entire perimeter (approximately 15 locations with 10 - 50 AREPs at each location) of your approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> ambient storage area in the back of your facility.\u003Cbr>\nb) There were rat AREPs along approximately 25% of the perimeter wall in the approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> middle area of the facility.\u003Cbr>\nc) There was a pallet of canned fish in jars with a cardboard box with seven jars of the canned fish also containing two apparent dead rats, cardboard nesting material, approximately 5 rat AREPs, an approximately 3\" x 1\" piece of pastry, possibly gingerbread, and five approximately 1\" x 1\" pieces of heart-shaped chocolates.\u003Cbr>\nd) There were approximately ten locations with holes chewed through cardboard and chewed cardboard on pallets containing food products such as buckwheat, rice, pasta, and jars of mushrooms.\u003Cbr>\ne) There was a large mass of shredded plastic, possibly nesting material, with a very strong smell of urine surrounded by approximately fifty large, rat AREPs, found behind a pallet of boxes of buckwheat.\u003Cbr>\nf) There was a pallet of jars of pickled tomatoes with a box containing an apparent dead rat, approximately 20 rat AREPs, and apparent nesting material.\u003Cbr>\ng) An apparent rodent gnaw hole was found on a bag of cavatappi pasta with manufacture date of 10\u002F14\u002F21 inside a case on a pallet of pasta.\u003Cbr>\nh) There was a strong smell of urine in the eastern side of the middle part of the facility.\u003Cbr>\ni) In the front part of the facility there was a pallet containing 3 cases of Tula Gingerbread with Cranberry Filling with manufacturing date 04\u002F16\u002F22. One case of the gingerbread had five apparently chewed packages, each also containing chewed product.\u003C\u002Fp>\n\n\u003Cp>The presence of pests in a food facility can result in illness to consumers through microbial contamination. Rodents are known sources of Salmonella and parasites that can cause foodborne illness. This is a repeat violation from the FDA inspection that ended on November 19, 2014, when FDA investigators observed apparent rodent excreta pellets and an apparent rat running across pallets of food product in the firm’s ambient temperature warehouse.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Samples\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Additionally, during the inspection, on September 8, 2022, FDA investigators collected samples for filth analysis by FDA laboratories and found the following violative results that support the above listed observations of rodent activities in your food storage areas.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Sample 1189839 consisting of apparent rodent excreta pellets and nesting material was examined and found to contain rat excreta pellets, rat hairs, double incisor chew marks, live mites, dead insects, and urea.\u003C\u002Fli>\n\t\u003Cli>Sample 1189840 consisting of an apparent gnawed bag of Cavatappi pasta was examined and found to have at least 6 double incisor marks.\u003C\u002Fli>\n\t\u003Cli>Sample 1189841 consisting of an apparent gnawed bag of Tula gingerbread filled with fruit and berry filling was examined and found to have rodent double incisor marks.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your response to this warning letter should include your corrective actions to clean these areas, exclude pests, your new frequency and procedure for sanitation monitoring for the exclusion of pests along with sanitation monitoring records for at least five production days to demonstrate implementation. For assistance with complying with 21 CFR § 123.11, you may consult the “Sanitation Control Procedures for Processing Fish and Fishery Products” document created by the Seafood HACCP Alliance available online at the following website http:\u002F\u002Fifasbooks.ifas.ufl.edu\u002Fp-99-sanitation-control-procedures-for-processing-fish-and-fishery-products.aspx.\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. You should take prompt action to address the violations noted in this letter. Failure to promptly address these violations may result in legal action without further notice, including, without limitation, seizure, injunction, or administrative action for suspension of food facility registration if criteria and conditions warrant.\u003C\u002Fp>\n\n\u003Cp>In addition to the above violations, we offer the following comment. To comply with 21 CFR § 123.10, you must have an individual who has successfully completed training in the application of HACCP principles to fish and fishery product processing that is at least equivalent to that received under a standardized curriculum recognized as adequate by the FDA or who may otherwise be qualified through job experience to perform the following functions: (1) the development of the HACCP plan, as required by 21 CFR § 123.6(b); (2) the reassessment and modification of the HACCP plan in accordance with the corrective action procedures specified in 21 CFR § 123.7(c)(5); (3) the reassessment and modification of the HACCP plan in accordance with the verification activities specified in 21 CFR § 123.8(a)(1);(4) the reassessment and modification of the hazard analysis in accordance with the verification activities specified in 21 CFR § 123.8(c); and (5) perform the record review required by 21 CFR § 123.8(a)(3). During the inspection you stated no one associated with your firm has completed seafood HACCP training. Further, based on the seafood HACCP violations described in this letter, it does not appear that any individual at your firm has sufficient seafood HACCP knowledge through job experience. You can view information on training and course availability from the Association of Food and Drug Officials (AFDO) at the following website https:\u002F\u002Fwww.afdo.org\u002Ftraining\u002Fsha\u002Fseafood-haccp\u002F.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written response should be sent electronically to: orahafwest5firmresponses@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Otherwise, a hardcopy response can be sent to:\u003C\u002Fp>\n\n\u003Cp>Sergio Chavez, Director, Compliance Branch\u003Cbr>\nFood and Drug Administration\u003Cbr>\nOffice of Human and Animal Food Operations West - Division 5\u003Cbr>\n1201 Harbor Bay Parkway\u003Cbr>\nAlameda, CA 94502\u003C\u002Fp>\n\n\u003Cp>Refer to Unique Identification Number, CMS 643578, when replying.\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding this letter, please contact Clarice J. Ahn, Compliance Officer, at clarice.ahn@fda.hhs.gov, or 510-337-6854.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Darla R. Bracy\u003Cbr>\nDistrict Director | FDA San Francisco District\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food Operations West - Division 5\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUnited Parcel Service\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Boris Dinerman\n\nRecipient Title\n\nCEO\n\nRDM Express Inc.\n\n2000 McKinnon Ave. Bldg. 427, Unit #12\n\nSan Francisco, CA 94124\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations West V\n\nUnited States\n\nWARNING LETTER\n\nDecember 12, 2022\n\nWL 643578\n\nDear Mr. Dinerman:\n\nThe United States Food and Drug Administration (FDA) inspected your ambient, refrigerated, and frozen warehouse facility, located at 2000 McKinnon Ave., Bldg. 427, Unit 12, San Francisco, CA 94124, from September 05-15, 2022. During the inspection, FDA investigators found serious violations of the seafood Hazard Analysis and Critical Control Point (HACCP) regulation, Title 21, Code of Federal Regulations (CFR), Part 123 (21 CFR Part 123), and the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP & PC rule) (21 CFR Part 117). At the conclusion of the inspection, the FDA investigators issued a Form FDA 483, Inspectional Observations, listing the deviations found at your firm. In addition, FDA investigators collected filth samples from various areas within your warehouse facility. FDA laboratory analyses of the samples found the presence of rodent and insect activity throughout your facility.\n\nIn accordance with 21 CFR § 123.6(g), failure of a processor of fish or fishery products to have and implement a HACCP plan that complies with this section or otherwise operate in accordance with the requirements of Part 123, renders the fish or fishery products adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 342(a)(4). Based on our inspectional findings and analytical results, we have determined that the food products stored at your facility, including the ready-to-eat, refrigerated, reduced oxygen packaging Herring Fillets in Oil, are adulterated within the meaning of section 402(a)(4) of the Act in that they have been prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth or rendered injurious to health. You may find the Act, the seafood HACCP regulation, the 4th edition of the Fish and Fisheries Products Hazards & Controls Guidance, and further information about the CGMP & PC rule through links in FDA's home page at www.fda.gov.\n\nAt the conclusion of the inspection, FDA investigators issued you a Form FDA 483, Inspectional Observations. You have not submitted a response to address these violations. Based on our review of the inspectional findings, we are issuing this letter to advise you of FDA’s continuing concerns and to provide detailed information describing the findings at your facility.\n\nSeafood HACCP\n\n1. You must implement the monitoring procedures that you have listed in your HACCP plan, to comply with 21 CFR § 123.6 (b). However, your firm did not implement the following monitoring procedures as listed in your HACCP plan for Herring Fillets in Oil.\n\na) You did not visually check the data generated by a temperature recording device during transit at your receiving critical control point (CCP) to control the listed hazards of C. botulinum toxin and histamine formation.\n\nSpecifically, on August 29, 2022, you received the following Herring Fillets in Oil products:\n\n(b)(4)\n\nUpon receipt of these reduced oxygen packaging (ROP), ready-to-eat (RTE) products, you did not review any transportation records as required by your HACCP plan. You explained to the investigator that your standard practice is (b)(4) to obtain a temperature upon receipt and record the temperature on your receiving log. This procedure is not what your plan requires, it is not adequate to ensure that proper temperatures were maintained during transit, and it is a repeat violation from your FDA inspection that ended on December 6, 2017.\n\nb) You did not check a continuous temperature recording for your cooler (b)(4) as required by your HACCP plan at your refrigerated storage CCP with a critical limit of “Cooler temperature of (b)(4)” to control for the listed hazards of pathogenic bacteria growth and toxin formation, C. botulinum toxin formation, and histamine formation. Specifically, your cooler does not have a continuous temperature monitoring device. Additionally, you stated to the investigator that your standard practice is to (b)(4). This procedure is not what your plan requires and is not adequate to ensure that a proper temperature is maintained in the cooler.\n\nRegarding the inadequacy of your monitoring, on September 7, 2022, our investigators used a calibrated traceable thermometer to take the following temperature readings from the cooler where you stored all your refrigerated seafood products, including ROP, RTE Herring Fillet in Oil:\n\nAt 8:15 AM, the cooler temperature readout was 46.9°F\n\nAt 1:30 PM, the cooler temperature readout was 54.6°F\n\nAt 3:10 PM, the cooler temperature readout was 58.4°F\n\nFurthermore, you did not have documentation showing that the thermometers you use have been calibrated for accuracy to comply with 21 CFR § 123.8 (a)(2)(ii) for the calibration of process-monitoring instruments. These are repeat violations from your FDA inspection that ended on December 6, 2017. We note that during the inspection you moved all your seafood products from the cooler to the freezer. Further, you stated that all seafood products will be stored in the freezer until you are able to install a continuous monitoring system for the cooler.\n\n2. Because you chose to include a corrective action plan in your HACCP plan your described corrective actions must be appropriate to comply with 21 CFR § 123.7 (b). However, your corrective action plan for your Herring Fillets in Oil listed hazards of pathogenic bacteria growth and toxin formation, C. botulinum toxin formation, and histamine formation at the Receiving and Refrigerated Storage CCPs is not appropriate. Your corrective actions fail to ensure the cause of the deviation is corrected, such as discontinuing the use of the supplier until transit practices have improved and adjusting or repairing the cooler.\n\nYour response to this warning letter should include the disposition of the product affected by the temperature deviation during refrigerated storage, and a revised HACCP plan along with at least five production days of CCP monitoring records to demonstrate implementation.\n\nSanitation\n\n1. You must monitor the conditions and practices during processing with sufficient frequency to ensure conformance with the current good manufacturing practice requirements in 21 CFR Part 117, Subpart B (CGMPs), that are both appropriate to your plant and the food being processed and relate to one of the areas specified in 21 CFR § 123.11(b)(1)-(8), to comply with 21 CFR § 123.11 (b). However, your firm did not monitor for the presence of pests in the food plant with sufficient frequency to ensure that pests are not allowed in any area, as required by 21 CFR § 117.35(C). This is related to the exclusion of pests from the food plant, 21 CFR § 123.11 (b)(8). Specifically, on September 7 and 8, 2022, our investigators observed the following in your ambient food storage area:\n\na) There were many large, rat apparent rodent excreta pellets (AREPs) found along the entire perimeter (approximately 15 locations with 10 - 50 AREPs at each location) of your approximately (b)(4) ambient storage area in the back of your facility.\n\nb) There were rat AREPs along approximately 25% of the perimeter wall in the approximately (b)(4) middle area of the facility.\n\nc) There was a pallet of canned fish in jars with a cardboard box with seven jars of the canned fish also containing two apparent dead rats, cardboard nesting material, approximately 5 rat AREPs, an approximately 3\" x 1\" piece of pastry, possibly gingerbread, and five approximately 1\" x 1\" pieces of heart-shaped chocolates.\n\nd) There were approximately ten locations with holes chewed through cardboard and chewed cardboard on pallets containing food products such as buckwheat, rice, pasta, and jars of mushrooms.\n\ne) There was a large mass of shredded plastic, possibly nesting material, with a very strong smell of urine surrounded by approximately fifty large, rat AREPs, found behind a pallet of boxes of buckwheat.\n\nf) There was a pallet of jars of pickled tomatoes with a box containing an apparent dead rat, approximately 20 rat AREPs, and apparent nesting material.\n\ng) An apparent rodent gnaw hole was found on a bag of cavatappi pasta with manufacture date of 10\u002F14\u002F21 inside a case on a pallet of pasta.\n\nh) There was a strong smell of urine in the eastern side of the middle part of the facility.\n\ni) In the front part of the facility there was a pallet containing 3 cases of Tula Gingerbread with Cranberry Filling with manufacturing date 04\u002F16\u002F22. One case of the gingerbread had five apparently chewed packages, each also containing chewed product.\n\nThe presence of pests in a food facility can result in illness to consumers through microbial contamination. Rodents are known sources of Salmonella and parasites that can cause foodborne illness. This is a repeat violation from the FDA inspection that ended on November 19, 2014, when FDA investigators observed apparent rodent excreta pellets and an apparent rat running across pallets of food product in the firm’s ambient temperature warehouse.\n\nSamples\n\nAdditionally, during the inspection, on September 8, 2022, FDA investigators collected samples for filth analysis by FDA laboratories and found the following violative results that support the above listed observations of rodent activities in your food storage areas.\n\nSample 1189839 consisting of apparent rodent excreta pellets and nesting material was examined and found to contain rat excreta pellets, rat hairs, double incisor chew marks, live mites, dead insects, and urea.\n\nSample 1189840 consisting of an apparent gnawed bag of Cavatappi pasta was examined and found to have at least 6 double incisor marks.\n\nSample 1189841 consisting of an apparent gnawed bag of Tula gingerbread filled with fruit and berry filling was examined and found to have rodent double incisor marks.\n\nYour response to this warning letter should include your corrective actions to clean these areas, exclude pests, your new frequency and procedure for sanitation monitoring for the exclusion of pests along with sanitation monitoring records for at least five production days to demonstrate implementation. For assistance with complying with 21 CFR § 123.11, you may consult the “Sanitation Control Procedures for Processing Fish and Fishery Products” document created by the Seafood HACCP Alliance available online at the following website http:\u002F\u002Fifasbooks.ifas.ufl.edu\u002Fp-99-sanitation-control-procedures-for-processing-fish-and-fishery-products.aspx.\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. You should take prompt action to address the violations noted in this letter. Failure to promptly address these violations may result in legal action without further notice, including, without limitation, seizure, injunction, or administrative action for suspension of food facility registration if criteria and conditions warrant.\n\nIn addition to the above violations, we offer the following comment. To comply with 21 CFR § 123.10, you must have an individual who has successfully completed training in the application of HACCP principles to fish and fishery product processing that is at least equivalent to that received under a standardized curriculum recognized as adequate by the FDA or who may otherwise be qualified through job experience to perform the following functions: (1) the development of the HACCP plan, as required by 21 CFR § 123.6(b); (2) the reassessment and modification of the HACCP plan in accordance with the corrective action procedures specified in 21 CFR § 123.7(c)(5); (3) the reassessment and modification of the HACCP plan in accordance with the verification activities specified in 21 CFR § 123.8(a)(1);(4) the reassessment and modification of the hazard analysis in accordance with the verification activities specified in 21 CFR § 123.8(c); and (5) perform the record review required by 21 CFR § 123.8(a)(3). During the inspection you stated no one associated with your firm has completed seafood HACCP training. Further, based on the seafood HACCP violations described in this letter, it does not appear that any individual at your firm has sufficient seafood HACCP knowledge through job experience. You can view information on training and course availability from the Association of Food and Drug Officials (AFDO) at the following website https:\u002F\u002Fwww.afdo.org\u002Ftraining\u002Fsha\u002Fseafood-haccp\u002F.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour written response should be sent electronically to: orahafwest5firmresponses@fda.hhs.gov.\n\nOtherwise, a hardcopy response can be sent to:\n\nSergio Chavez, Director, Compliance Branch\n\nFood and Drug Administration\n\nOffice of Human and Animal Food Operations West - Division 5\n\n1201 Harbor Bay Parkway\n\nAlameda, CA 94502\n\nRefer to Unique Identification Number, CMS 643578, when replying.\n\nIf you have questions regarding this letter, please contact Clarice J. Ahn, Compliance Officer, at clarice.ahn@fda.hhs.gov, or 510-337-6854.\n\nSincerely,\n\n\u002FS\u002F\n\nDarla R. Bracy\n\nDistrict Director | FDA San Francisco District\n\nProgram Division Director\n\nOffice of Human and Animal Food Operations West - Division 5","rdm-express-inc-643578-12122022","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frdm-express-inc-643578-12122022","2026-10-26T08:09:47.56949+00:00","2023-02-28","643578","Division of Human and Animal Food Operations West V","2026-08-20T01:13:59.779+00:00","United Parcel Service","2022-12-12",{"id":52,"raw":53,"subject":58,"body_html":59,"body_text":60,"firm_name":61,"letter_id":62,"created_at":63,"fei_number":19,"letter_url":64,"updated_at":65,"action_type":22,"case_status":23,"posted_date":66,"marcs_cms_no":67,"product_type":26,"closeout_date":19,"issuing_office":57,"recipient_name":68,"body_fetched_at":69,"delivery_method":70,"recipient_title":19,"reference_number":19,"action_taken_date":71,"medical_device_id":19,"response_letter_date":19},186,[54,55,56,57,58,13,13,13],"\u003Ctime datetime=\"2026-05-05T04:00:00Z\">05\u002F05\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-04-24T04:00:00Z\">04\u002F24\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgreenworld-food-express-llc-728188-04242026\">Greenworld Food Express LLC\u003C\u002Fa>","Office of Inspections and Investigations","Foreign Supplier Verification Program (FSVP)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL AND UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Bashir Harb\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Greenworld Food Express LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>27165 Wick Rd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Taylor\u003C\u002Fspan>, \u003Cspan>MI\u003C\u002Fspan> \u003Cspan>48180-3016\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Marwa.harb@greenworld.ca\"> Marwa.harb@greenworld.ca\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Inspections and Investigations\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>April 24, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Re: CMS 728188\u003C\u002Fp>\u003Cp>Dear Mr. Harb\u003C\u002Fp>\u003Cp>On April 2, 2026, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Greenworld Food Express (USA) LLC located at 27165 Wick Rd, Taylor, MI 48180-3016. This inspection was conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\u003C\u002Fp>\u003Cp>During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act. At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations. We acknowledge receipt of your response, dated 04\u002F07\u002F2026 in which you stated that you will need the maximum time allowed to have the FSVP program completed and in compliance. We are unable to evaluate the adequacy of your response because you have not provided any supporting documentation demonstrating your corrective actions.\u003C\u002Fp>\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\u003Cp>You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import, including each of the following foods:\u003C\u002Fp>\u003Cul>\u003Cli>Halwa Pistachio imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>Royal Zaatar imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>Tahini imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003C\u002Ful>\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html.\u003C\u002Fp>\u003Cp>In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\u003Cp>Please send your reply to:\u003C\u002Fp>\u003Cp>Food and Drug Administration\u003Cbr>Attention: Joseph DiNardo, Compliance Officer\u003Cbr>622 Main St, Suite 100\u003Cbr>Buffalo, NY 14202\u003C\u002Fp>\u003Cp>If you have any questions regarding this letter, or wish to send your response electronically, you may contact Joseph DiNardo via email at joseph.dinardo@fda.hhs.gov. Please reference CMS #728188 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Michael Giammanco\u003Cbr>Acting Program Division Director\u003Cbr>Division of Northern Border Imports\u003C\u002Fp>\u003Cp>&nbsp;\u003C\u002Fp>\u003Cp>Cc:\u003Cbr>Miss Marwa Harb\u003Cbr>Greenworld Food Express (USA) LLC\u003Cbr>27165 Wick Rd\u003Cbr>Taylor, MI 48180-3016&nbsp;&nbsp;\u003Cbr>marwa.harb@greenworld.ca&nbsp;&nbsp;\u003Cbr>FEI 3033575856\u003Cbr>&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL AND UNITED PARCEL SERVICE\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Bashir Harb\n\nRecipient Title\n\nOwner\n\nGreenworld Food Express LLC\n\n27165 Wick Rd\n\nTaylor, MI 48180-3016\n\nUnited States\n\nMarwa.harb@greenworld.ca\n\nIssuing Office:\n\nOffice of Inspections and Investigations\n\nUnited States\n\nApril 24, 2026\nWARNING LETTER\nRe: CMS 728188\nDear Mr. Harb\nOn April 2, 2026, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Greenworld Food Express (USA) LLC located at 27165 Wick Rd, Taylor, MI 48180-3016. This inspection was conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\nDuring the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&C Act. At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations. We acknowledge receipt of your response, dated 04\u002F07\u002F2026 in which you stated that you will need the maximum time allowed to have the FSVP program completed and in compliance. We are unable to evaluate the adequacy of your response because you have not provided any supporting documentation demonstrating your corrective actions.\nYour significant violations of the FSVP regulation are as follows:\nYou did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import, including each of the following foods:\nHalwa Pistachio imported from (b)(4)\nRoyal Zaatar imported from (b)(4)\nTahini imported from (b)(4)\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1, subpart L.\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html.\nIn addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\nPlease send your reply to:\nFood and Drug Administration\nAttention: Joseph DiNardo, Compliance Officer\n622 Main St, Suite 100\nBuffalo, NY 14202\nIf you have any questions regarding this letter, or wish to send your response electronically, you may contact Joseph DiNardo via email at joseph.dinardo@fda.hhs.gov. Please reference CMS #728188 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\nSincerely,\n\u002FS\u002F\nMichael Giammanco\nActing Program Division Director\nDivision of Northern Border Imports\n\nCc:\nMiss Marwa Harb\nGreenworld Food Express (USA) LLC\n27165 Wick Rd\nTaylor, MI 48180-3016\nmarwa.harb@greenworld.ca\nFEI 3033575856","Greenworld Food Express LLC","greenworld-food-express-llc-728188-04242026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgreenworld-food-express-llc-728188-04242026","2026-10-26T08:08:50.516549+00:00","2026-05-05","728188","Mr. Bashir Harb","2026-08-19T04:43:55.253+00:00","VIA EMAIL AND UNITED PARCEL SERVICE","2026-04-24",{"id":73,"raw":74,"subject":79,"body_html":80,"body_text":81,"firm_name":82,"letter_id":83,"created_at":84,"fei_number":19,"letter_url":85,"updated_at":86,"action_type":22,"case_status":23,"posted_date":87,"marcs_cms_no":88,"product_type":89,"closeout_date":19,"issuing_office":78,"recipient_name":90,"body_fetched_at":91,"delivery_method":92,"recipient_title":19,"reference_number":19,"action_taken_date":93,"medical_device_id":19,"response_letter_date":19},677,[75,76,77,78,79,13,13,13],"\u003Ctime datetime=\"2025-09-02T04:00:00Z\">09\u002F02\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-08-25T04:00:00Z\">08\u002F25\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmy-holistic-honey-co-shenzhen-qanhai-wanb-express-supply-chain-co-ltd-712052-08252025\">My Holistic Honey c\u002Fo Shenzhen Qanhai Wanb Express Supply Chain Co., LTD \u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","Unapproved New Drugs\u002FOphthalmic Drug Products","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Bingbing Feng\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>My Holistic Honey c\u002Fo Shenzhen Qanhai Wanb Express Supply Chain Co., LTD \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2452 Gillingham Circle\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Thousand Oaks\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>91362\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:support@myholistichoney.com\"> support@myholistichoney.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>August 25, 2025\u003C\u002Fp>\u003Cp>RE: 712052\u003C\u002Fp>\u003Cp>Dear Bingbing Feng:\u003C\u002Fp>\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your product label and your website at the Internet address https:\u002F\u002Fmyholistichoney.com\u002F in July 2025. The FDA has observed that your website offers “Holistic Honey EYE DROP” (also referred to on your website as “Jimerito Honey Eye Drops”) for sale in the United States. Based on our review, this product is an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering this product for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>Your “Holistic Honey EYE DROP” product is especially concerning from a public health perspective. Ophthalmic drug products, which are intended for administration into the eyes, in general pose a greater risk of harm to users because the route of administration for these products bypasses some of the body’s natural defenses.\u003C\u002Fp>\u003Cp>Based on a review of your product label and website, your “Holistic Honey EYE DROP” is a drug under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples of claims that provide evidence of the intended use of this product as a drug include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>From your product label:\u003C\u002Fp>\u003Cul>\u003Cli>“HOLISTIC HONEY EYE DROP OPTIMAL VISION”\u003C\u002Fli>\u003Cli>“It can quickly releve [sic] eye dryness and fatigue and restore eye comfort.”\u003C\u002Fli>\u003Cli>“\u003Cstrong>Noticeable relief &amp; soothing comfort\u003C\u002Fstrong>\u003Cbr>My optometrist recommended Holistic Honey for my chronic dry eye condition, and I'm so glad they did. I finally have relief without having to rely on prescription medications!”\u003C\u002Fli>\u003Cli>“Naturally promotes healing, reduces inflammation, and soothes irritation.”\u003C\u002Fli>\u003Cli>“\u003Cstrong>Fight Off Eye Fatigue Instantly\u003C\u002Fstrong>\u003Cbr>Provides immediate comfort &amp; moisture to tired, strained eyes, making them feel refreshed &amp; alert.”\u003C\u002Fli>\u003Cli>“\u003Cstrong>Give Your Eyes a Natural Boost\u003C\u002Fstrong>\u003Cbr>Crafted with natural ingredients to help your eyes feel their best. It addresses dryness, irritation, and discomfort.”\u003C\u002Fli>\u003Cli>“\u003Cstrong>Experience Newfound Clarity\u003C\u002Fstrong>\u003Cbr>By providing essential hydration and lubrication to your eyes.”\u003C\u002Fli>\u003Cli>“\u003Cstrong>Supports Overall Eye Comfort\u003C\u002Fstrong>\u003Cbr>Supports healthy blood flow and helps maintain comfortable vision.”\u003C\u002Fli>\u003Cli>“\u003Cstrong>Modern Life Takes a Toll on Your Eyes. Holistic Honey Fights Back\u003C\u002Fstrong>.\u003Cbr>Our eyes work hard in today's digital world, and many of us experience dryness, strain, and discomfort—issues that can contribute to more serious conditions like cataracts or glaucoma over time. Holistic Honey is crafted with the power of nature (honey!) to address these very issues.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Unlike traditional eye drops, Holistic Honey goes beyond just moisture. They provide a natural solution to promote healthier, more comfortable eyes and help reduce the risk of long-term vision problems.”\u003C\u002Fp>\u003Cp>Your “Holistic Honey EYE DROP” is not generally recognized as safe and effective (GRASE) for its above referenced uses and, therefore, this product is a “new drug” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). There is no FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, in effect for this product. Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your product is not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\u003C\u002Fp>\u003Cp>Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov. Please include your firm name and the unique identifier “712052” in the subject line of the email.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>Food and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nBingbing Feng\n\nMy Holistic Honey c\u002Fo Shenzhen Qanhai Wanb Express Supply Chain Co., LTD\n\n2452 Gillingham Circle\n\nThousand Oaks, CA 91362\n\nUnited States\n\nsupport@myholistichoney.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter\nAugust 25, 2025\nRE: 712052\nDear Bingbing Feng:\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your product label and your website at the Internet address https:\u002F\u002Fmyholistichoney.com\u002F in July 2025. The FDA has observed that your website offers “Holistic Honey EYE DROP” (also referred to on your website as “Jimerito Honey Eye Drops”) for sale in the United States. Based on our review, this product is an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering this product for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nYour “Holistic Honey EYE DROP” product is especially concerning from a public health perspective. Ophthalmic drug products, which are intended for administration into the eyes, in general pose a greater risk of harm to users because the route of administration for these products bypasses some of the body’s natural defenses.\nBased on a review of your product label and website, your “Holistic Honey EYE DROP” is a drug under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples of claims that provide evidence of the intended use of this product as a drug include, but may not be limited to, the following:\nFrom your product label:\n“HOLISTIC HONEY EYE DROP OPTIMAL VISION”\n“It can quickly releve [sic] eye dryness and fatigue and restore eye comfort.”\n“Noticeable relief & soothing comfort\nMy optometrist recommended Holistic Honey for my chronic dry eye condition, and I'm so glad they did. I finally have relief without having to rely on prescription medications!”\n“Naturally promotes healing, reduces inflammation, and soothes irritation.”\n“Fight Off Eye Fatigue Instantly\nProvides immediate comfort & moisture to tired, strained eyes, making them feel refreshed & alert.”\n“Give Your Eyes a Natural Boost\nCrafted with natural ingredients to help your eyes feel their best. It addresses dryness, irritation, and discomfort.”\n“Experience Newfound Clarity\nBy providing essential hydration and lubrication to your eyes.”\n“Supports Overall Eye Comfort\nSupports healthy blood flow and helps maintain comfortable vision.”\n“Modern Life Takes a Toll on Your Eyes. Holistic Honey Fights Back.\nOur eyes work hard in today's digital world, and many of us experience dryness, strain, and discomfort—issues that can contribute to more serious conditions like cataracts or glaucoma over time. Holistic Honey is crafted with the power of nature (honey!) to address these very issues.\nUnlike traditional eye drops, Holistic Honey goes beyond just moisture. They provide a natural solution to promote healthier, more comfortable eyes and help reduce the risk of long-term vision problems.”\nYour “Holistic Honey EYE DROP” is not generally recognized as safe and effective (GRASE) for its above referenced uses and, therefore, this product is a “new drug” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). There is no FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, in effect for this product. Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your product is not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\nYour response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov. Please include your firm name and the unique identifier “712052” in the subject line of the email.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nFood and Drug Administration","My Holistic Honey c\u002Fo Shenzhen Qanhai Wanb Express Supply Chain Co., LTD","my-holistic-honey-co-shenzhen-qanhai-wanb-express-supply-chain-co-ltd-712052-08252025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmy-holistic-honey-co-shenzhen-qanhai-wanb-express-supply-chain-co-ltd-712052-08252025","2026-10-26T08:09:29.02339+00:00","2025-09-02","712052","Drugs","Bingbing Feng","2026-08-19T16:27:24.345+00:00","Via Email","2025-08-25",4,{"510k":96,"classification":97,"enforcement":98,"event":99,"event_backfill":100,"pma":101,"warning_letter":102},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-20T04:00:32.497+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]